BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Quality Index
BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Quality Index of 0.76x as of December 2025. Operating cash flow of $276.04 Million is below net income of $362.26 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore BCRX cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BioCryst Pharmaceuticals Inc Cash Flow Quality Index (2025–2025)
Historical Cash Flow Quality Index for BioCryst Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BCRX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BioCryst Pharmaceuticals Inc (2025–2025)
Year-by-year earnings quality comparison for BioCryst Pharmaceuticals Inc. For live market cap and the full company financial profile, see BCRX stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.25x | $329.88 Million | $263.86 Million | — |